Canary Global
Biotechnology company developing RNA-based therapeutics and companion diagnostics. Focus areas include siRNA and anti-miR therapeutics, LNP-encapsulated mRNA for systemic and CNS delivery, antibody-guided and AAV-based vector design for CNS gene therapy, AI-driven target and biomarker selection from large human datasets, and a molecular point-of-care diagnostic platform that combines a disposable cartridge with cloud analytics. Programs span preclinical in vivo development for metabolic and neurological disorders and development of companion diagnostics for trial enrollment and monitoring.
Industries
Nr. of Employees
small (1-50)
Canary Global
Products
Preclinical dual‑gene siRNA therapeutic candidate for obesity
A preclinical dual‑component siRNA candidate designed to promote reprogramming of white adipocytes to energy‑expending beige adipocytes, reduce fat mass, preserve lean mass and improve metabolic parameters; being advanced toward clinical development.
Molecular point‑of‑care miRNA diagnostic platform (lab‑on‑a‑chip)
Disposable multi‑target cartridge and portable hub for one‑step nucleic acid amplification with cloud analytics and a mobile app for interpretation of miRNA expression patterns to enable early detection and trial stratification.
LNP‑encapsulated mRNA formulations for CNS and rare pediatric disorders
LNP‑encapsulated mRNA formulations designed for targeted delivery to CNS cells and for replacement of defective proteins in rare pediatric disorders such as leukodystrophies, and for therapies addressing leptin deficiency/resistance in pediatric obesity.
Preclinical dual‑gene siRNA therapeutic candidate for obesity
A preclinical dual‑component siRNA candidate designed to promote reprogramming of white adipocytes to energy‑expending beige adipocytes, reduce fat mass, preserve lean mass and improve metabolic parameters; being advanced toward clinical development.
Molecular point‑of‑care miRNA diagnostic platform (lab‑on‑a‑chip)
Disposable multi‑target cartridge and portable hub for one‑step nucleic acid amplification with cloud analytics and a mobile app for interpretation of miRNA expression patterns to enable early detection and trial stratification.
LNP‑encapsulated mRNA formulations for CNS and rare pediatric disorders
LNP‑encapsulated mRNA formulations designed for targeted delivery to CNS cells and for replacement of defective proteins in rare pediatric disorders such as leukodystrophies, and for therapies addressing leptin deficiency/resistance in pediatric obesity.
Services
Discovery and preclinical development of siRNA, anti‑miR and mRNA therapeutic candidates for metabolic, neurological and rare genetic diseases, including in vivo efficacy and translational assays.
Development of miRNA-based companion diagnostics and a molecular lab‑on‑a‑chip platform with cloud analytics for early detection, patient stratification and clinical trial monitoring.
Automated oligonucleotide synthesis, purification and analytical characterization services to support discovery, lead optimization and CMC transition activities.
Discovery and preclinical development of siRNA, anti‑miR and mRNA therapeutic candidates for metabolic, neurological and rare genetic diseases, including in vivo efficacy and translational assays.
Development of miRNA-based companion diagnostics and a molecular lab‑on‑a‑chip platform with cloud analytics for early detection, patient stratification and clinical trial monitoring.
Automated oligonucleotide synthesis, purification and analytical characterization services to support discovery, lead optimization and CMC transition activities.
Expertise Areas
- RNA therapeutics (siRNA and anti‑miR)
- Lipid nanoparticle (LNP) mRNA delivery and engineering
- CNS-directed gene therapy and vector design
- miRNA biomarker discovery and companion diagnostics
Key Technologies
- RNA interference (siRNA)
- Anti‑miR therapeutics
- Lipid nanoparticles (LNP) for mRNA delivery
- Adeno‑associated virus (AAV) vectors
News & Updates
Announcement of clinical leadership appointment to advance the lead siRNA candidate into Phase 1 clinical development.
Preclinical results reported for a dual siRNA candidate demonstrating weight loss, fat reduction and lean mass preservation with potential for infrequent dosing.
Company accepted into Canada's SR&ED program to support R&D work.
Participation in Canada's Scientific Research & Experimental Development program to support R&D activities.
Announcement of clinical leadership appointment to advance the lead siRNA candidate into Phase 1 clinical development.
Preclinical results reported for a dual siRNA candidate demonstrating weight loss, fat reduction and lean mass preservation with potential for infrequent dosing.
Company accepted into Canada's SR&ED program to support R&D work.
Participation in Canada's Scientific Research & Experimental Development program to support R&D activities.